Rate of early onset Alzheimer's disease: a systematic review and meta-analysis
- PMID: 25815299
- PMCID: PMC4356853
- DOI: 10.3978/j.issn.2305-5839.2015.01.19
Rate of early onset Alzheimer's disease: a systematic review and meta-analysis
Erratum in
-
Erratum to Rate of early onset Alzheimer's disease: a systematic review and meta-analysis.Ann Transl Med. 2016 May;4(9):E4. doi: 10.21037/atm.2016.05.21. Ann Transl Med. 2016. PMID: 27275503 Free PMC article.
Abstract
It is generally accepted that the population rate of early onset Alzheimer's disease (EOAD) in Alzheimer's disease (AD) is 1-2%. However, the true population based rate of EOAD has never been verified by a systematic review and meta-analysis. We used electronic searches of Cochrane Library, Embase, Medline and PubMed databases to identify published related studies. The systematic review and meta-analysis was then to be conducted to calculate a pooled rate of EOAD and make comparisons between studies and geographic distribution. A total of 13 papers were included in our systematic review and meta-analysis. The rate of EOAD, 5.5% [95% confidence interval (CI): 0.039-0.079, P<0.001], was generated after pooled analysis of all studies in random effect model. The pooled analysis of the rate in developed country was 5.9% (95% CI: 0.040-0.085, P<0.001). The pooled analysis of the rate in developing countries was 4.4% (95% CI: 0.028-0.066, P<0.001). Our study showed that the rate of EOAD in AD is 5.5%, not 1-2% as usually demonstrated. And our results indicated that the rate in developed countries was relative higher than in developing countries. Further trials with larger samples across more countries and more careful designed of experiments are required to confirm whether our findings are truly significant.
Keywords: Alzheimer’s disease (AD); Early onset Alzheimer’s disease (EOAD); meta-analysis; rate.
Figures




Similar articles
-
Early-onset Alzheimer's disease: a global cross-sectional analysis.Eur J Neurol. 2014 Sep;21(9):1149-54, e64-5. doi: 10.1111/ene.12453. Epub 2014 Apr 30. Eur J Neurol. 2014. PMID: 24780092
-
Non-Ashkenazi Jewish Origin is Associated with Early Onset Alzheimer's Disease.J Alzheimers Dis. 2018;65(3):877-884. doi: 10.3233/JAD-180331. J Alzheimers Dis. 2018. PMID: 30103328
-
The role of ethnicity, biological sex, and psychotropic agents in early and late onset Alzheimer's disease.Front Aging Neurosci. 2022 Dec 22;14:1052330. doi: 10.3389/fnagi.2022.1052330. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36620767 Free PMC article.
-
Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis.Expert Rev Neurother. 2019 Jun;19(6):475-480. doi: 10.1080/14737175.2019.1620106. Epub 2019 May 23. Expert Rev Neurother. 2019. PMID: 31092051
-
Ethical Considerations for Deep Brain Stimulation Trials in Patients with Early-Onset Alzheimer's Disease.J Alzheimers Dis. 2017;58(2):289-301. doi: 10.3233/JAD-161073. J Alzheimers Dis. 2017. PMID: 28436389 Review.
Cited by
-
Chronic pain in Alzheimer's disease: Endocannabinoid system.Exp Neurol. 2023 Feb;360:114287. doi: 10.1016/j.expneurol.2022.114287. Epub 2022 Nov 29. Exp Neurol. 2023. PMID: 36455638 Free PMC article. Review.
-
Relationship between the Presence of the ApoE ε4 Allele and EEG Complexity along the Alzheimer's Disease Continuum.Sensors (Basel). 2020 Jul 10;20(14):3849. doi: 10.3390/s20143849. Sensors (Basel). 2020. PMID: 32664228 Free PMC article.
-
Genomics: New Light on Alzheimer's Disease Research.Int J Mol Sci. 2018 Nov 27;19(12):3771. doi: 10.3390/ijms19123771. Int J Mol Sci. 2018. PMID: 30486438 Free PMC article. Review.
-
The Implication of Glial Metabotropic Glutamate Receptors in Alzheimer's Disease.Curr Neuropharmacol. 2023;21(2):164-182. doi: 10.2174/1570159X20666211223140303. Curr Neuropharmacol. 2023. PMID: 34951388 Free PMC article. Review.
-
Repeated exposure to novelty promotes resilience against the amyloid-beta effect through dopaminergic stimulation.Psychopharmacology (Berl). 2025 Jan;242(1):85-100. doi: 10.1007/s00213-024-06650-5. Epub 2024 Aug 15. Psychopharmacology (Berl). 2025. PMID: 39145803 Free PMC article.
References
-
- Jiang T, Yu JT, Tan L. Novel disease-modifying therapies for Alzheimer's disease. J Alzheimers Dis 2012;31:475-92. - PubMed
-
- Smits LL, Pijnenburg YA, Koedam EL, et al. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. J Alzheimers Dis 2012;30:101-8. - PubMed
-
- Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44. - PubMed
-
- Jiang T, Yu JT, Tian Y, et al. Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors. Curr Alzheimer Res 2013;10:852-67. - PubMed
LinkOut - more resources
Full Text Sources